Yuan-Ping Pang

Yuan-Ping Pang

Auto-generated profile, based on publicly available information

Yuan-Ping Pang

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in Nature
Verified
Journal Article
Closed access
PDF file
PMPiotr E. Marszalek
Piotr E. Marszalek
AOAndres F. Oberhauser
Andres F. Oberhauser
YPYuan-Ping Pang
Yuan-Ping Pang
JFJulio M. Fernandez
Julio M. Fernandez

21 March 2004 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MBMartin Bienengraeber
Martin Bienengraeber
TOTimothy M Olson
Timothy M Olson
VSVitaly A Selivanov
Vitaly A Selivanov
EKEva C Kathmann
Eva C Kathmann
FOFearghas O'COchlain
Fearghas O'COchlain
ATAndre Terzic
Andre Terzic
Stress tolerance of the heart requires high-fidelity metabolic sensing by ATP-sensitive potassium (KATP) channels that adjust membrane potential–dependent functions to match cellular energetic demand. Scanning of genomic DNA from individuals with heart failure and rhythm disturbances due to idiopathic dilated cardiomyopathy identified two mutations in ABCC9, which encodes the regulatory SUR2A subunit of the cardiac KATP channel. These missense and frameshift mutations mapped to evolutionarily conserved domains adjacent to the catalytic ATPase pocket within SUR2A. Mutant SUR2A proteins showed aberrant redistribution of conformations in the intrinsic ATP hydrolytic cycle, translating into abnormal KATP channel phenotypes with compromised metabolic signal decoding. Defective catalysis-mediated pore regulation is thus a mechanism for channel dysfunction and susceptibility to dilated cardiomyopathy.

1 January 1997 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
MRMia L. Raves
Mia L. Raves
MHMichal Harel
Michal Harel
YPYuan-Ping Pang
Yuan-Ping Pang
ISIsrael Silman
Israel Silman
AKAlan P. Kozikowski
Alan P. Kozikowski
Joel SussmanJoel Sussman
Joel Sussman

1 September 1996 in Journal of Biological Chemistry
Verified
Journal Article
Open access
YPYuan-Ping Pang
Yuan-Ping Pang
PQPolly Quiram
Polly Quiram
TJTanya Jelacic
Tanya Jelacic
FHFeng Hong
Feng Hong
SBStephen Brimijoin
Stephen Brimijoin
We report highly potent, selective, and low cost bifunctional acetylcholinesterase (AChE) inhibitors developed by our two-step prototype optimization strategy utilizing computer modeling of ligand docking with target proteins: 1) identify low affinity sites normally missed by x-ray crystallography; and 2) design bifunctional analogs capable of simultaneous binding at the computer-determined low affinity site and the x-ray-identified high affinity site. Applying this strategy to 9-amino-1,2,3,4-tetrahydroacridine (THA), a drug for Alzheimer's disease, we obtained alkylene linked bis-THA analogs. These analogs were up to 10,000-fold more selective and 1,000-fold more potent than THA in inhibiting rat AChE and yet required one simple reaction to synthesize. Additionally, alkylene linked benzyl-THA analogs were developed to examine the specificity of the docking-derived low affinity THA peripheral site in AChE. The present work and our previous computational studies strongly suggest that a low affinity THA peripheral site exists in AChE. This peripheral site provides a structural basis for design of improved cholinesterase ligands for treating Alzheimer's disease and for other health-related purposes.

4 July 2011 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
HDHaiming Dai
Haiming Dai
ASAlyson Smith
Alyson Smith
XMX. Wei Meng
X. Wei Meng
PSPaula A. Schneider
Paula A. Schneider
YPYuan-Ping Pang
Yuan-Ping Pang
SKScott Kaufmann
Scott Kaufmann
The mechanism by which the proapoptotic Bcl-2 family members Bax and Bak release cytochrome c from mitochondria is incompletely understood. In this paper, we show that activator BH3-only proteins bind tightly but transiently to the Bak hydrophobic BH3-binding groove to induce Bak oligomerization, liposome permeabilization, mitochondrial cytochrome c release, and cell death. Analysis by surface plasmon resonance indicated that the initial binding of BH3-only proteins to Bak occurred with similar kinetics with or without detergent or mitochondrial lipids, but these reagents increase the strength of the Bak–BH3-only protein interaction. Point mutations in Bak and reciprocal mutations in the BH3-only proteins not only confirmed the identity of the interacting residues at the Bak–BH3-only protein interface but also demonstrated specificity of complex formation in vitro and in a cellular context. These observations indicate that transient protein–protein interactions involving the Bak BH3-binding groove initiate Bak oligomerization and activation.

9 August 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EREdwin H. Rydberg
Edwin H. Rydberg
BBBoris Brumshtein
Boris Brumshtein
HGHarry M. Greenblatt
Harry M. Greenblatt
DWDawn Wong
Dawn Wong
DSDavid Shaya
David Shaya
Joel SussmanJoel Sussman
Joel Sussman